MOTS-c Peptide Dosage: A Physician's Protocol Guide

At a Glance

A correction for readers of earlier versions of this page: it stated that MOTS-c is not prohibited in sport. That was wrong. Unapproved substances fall under WADA’s S0 category.

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) sits in a category apart from most peptides discussed on this site. Unlike synthetic analogues of growth factors or modified fragments of naturally occurring proteins, MOTS-c is encoded directly in mitochondrial DNA — specifically in the 12S ribosomal RNA gene. It is one of a handful of mitochondria-derived peptides (MDPs) that communicate between the mitochondria and the rest of the cell, acting almost as a real-time readout of metabolic state.

What makes this clinically interesting is its mechanism. In mice, MOTS-c activates AMPK (AMP-activated protein kinase) — the same energy-sensing enzyme activated by exercise, caloric restriction, and metformin. But it does so through a distinct route involving the folate cycle, purine metabolism and AICAR, a purine biosynthesis intermediate that functions as a natural AMPK agonist [1]. The result is a coordinated metabolic shift: improved glucose handling and protection from diet-induced obesity and insulin resistance.

For people with metabolic inflexibility, early insulin resistance, or physical decline disproportionate to their age, MOTS-c has become one of the most discussed mitochondrial peptides. This guide covers how it is dosed, how it is cycled, and who is most likely to benefit — and what the evidence behind those protocols actually is.

People interested in a complementary mitochondrial peptide protocol should also review Humanin Peptide Dosage Protocol, which covers the sibling MDP with distinct neuroprotective and anti-apoptotic applications.

What MOTS-c is and what it does

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was described in 2015. In that first study, MOTS-c acted mainly on skeletal muscle, where it affected the folate cycle and purine metabolism, raised levels of the metabolite AICAR and activated AMPK, the cell’s energy sensor. Mice given MOTS-c were protected from diet-induced obesity and insulin resistance [1].

A 2021 study took the exercise angle further. MOTS-c improved physical performance in young, middle-aged and old mice, and intermittent treatment started late in life increased physical capacity and healthspan measures. The same paper showed that in humans, exercise increases MOTS-c in skeletal muscle and in circulation [2].

There is also a genetic thread: a MOTS-c gene variant (m.1382A>C) found in Northeast Asian populations has been proposed, as a hypothesis, as one contributor to Japanese longevity [3].

Taken together, MOTS-c looks like a real part of how mitochondria talk to the rest of the body. This translational picture shapes the practical approach: MOTS-c is most likely to matter in people who are already exercising, not as a substitute for physical activity. What we don’t yet know from human trials is whether injecting it into people does anything useful, at what dose, or with what side effects.

What the evidence shows

Preclinical

Human

The FDA states it has identified no human exposure data on drug products containing MOTS-c by any route [4]. The doses below therefore come from extrapolation of mouse work and from clinical practice, not from human trials.

Protocol table: doses at a glance

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No published human trial has given native MOTS-c. The only completed human study used a modified analogue, CB4211, and its results exist only as a company announcement. A phase 2a trial of MOTS-c in prediabetes is registered and recruiting (NCT07505745: fixed dose once daily for 12 weeks, dose not disclosed in the registry).

Weekly totals vary tenfold. The most commonly reported community pattern adds up to 5-10 mg per week. The protocol described in the next section (5-10 mg three to five times weekly) and the higher reference-site protocols add up to 15-50 mg per week. Nobody has compared these in people, and the mouse doses that started the interest (5-15 mg/kg) do not translate directly into either.

The one human signal comes from a different molecule. In the CB4211 phase 1b study, 20 obese adults with fatty liver received 25 mg of the analogue or placebo once daily for four weeks. The company reported that ALT fell by 21 percent and AST by 28 percent on CB4211 (versus a 4 percent rise and an 11 percent fall on placebo), glucose fell by 6 percent, and body weight showed only a trend. Liver fat fell by a similar amount in both groups. The only adverse events in more than 10 percent of treated subjects were mild to moderate injection-site reactions. CB4211 is a modified analogue, so none of this transfers automatically to MOTS-c itself.

Titration as it is actually done. Many users start low (0.5-1 mg, or a single 5 mg dose) because higher starting doses are linked in reports to fatigue, flushing or histamine-type reactions. Several describe feeling better after lowering the dose, for example moving from 5 mg three times weekly to 3.33 mg three times weekly.

What happens after stopping. There are no data. Community reports do not describe withdrawal or rebound effects, and nothing is known about whether any metabolic change persists.

Technique, reconstitution and storage are in the peptide injection guide.

Standard Dosage Protocols

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Starting Protocol (Weeks 1–2)

The most common community pattern is 5–10 mg per week in total, split into two or three injections (for example 3.33 mg three times weekly; Practice protocol). A frequent per-injection pattern starts at 5 mg subcutaneously, three times per week (e.g., Monday / Wednesday / Friday), administered 30–60 minutes before the morning training session (Anecdotal). This dose is intended to produce AMPK activation while allowing individual response to be assessed before increasing.

Commonly reported at 5 mg:

• Improved exercise-session energy within the first 1–2 weeks
• Mild reduction in post-meal glucose variability (captured on CGM if worn)
• Occasional transient warmth or mild flushing at the injection site — a self-limiting vasodilatory response

If the 5 mg dose is well-tolerated and the goals include stronger metabolic or anti-ageing effects, the usual step is to advance to the maintenance range after two weeks.

Maintenance Protocol (Weeks 3–8)

The higher maintenance range is 5–10 mg, three to five times per week, with 10 mg four times weekly inside that range. This comes from a single reference source (Peptide DB lists 5–10 mg daily for metabolic goals) and from community reports, so it is Anecdotal; it adds up to 15–50 mg a week, against 5–10 mg a week in the most common community pattern. Injection timing remains pre-exercise when possible, though a fixed morning window (within 60 minutes of waking) is an acceptable alternative for non-exercising days.

For metabolic syndrome and insulin resistance as primary indications, reference-site protocols tend toward the upper end: 10 mg × 5 days per week, alongside lifestyle measures (Anecdotal). CGM and fasting insulin are re-checked at week 6.

For longevity and anti-ageing as primary goals in otherwise healthy people, 5–10 mg × 3 times per week is used (Anecdotal); the same reference source lists 15 mg three times weekly for anti-ageing.

Advanced Dosing (Single Reference Source)

Some protocols, chiefly the Peptide DB reference page, extend to 15 mg per injection (Anecdotal), primarily in people with significant insulin resistance or metabolic dysfunction; there is no published human trial at this or any other dose. This range is generally reserved for cases in which lower doses have produced a plateau in response and the indication remains compelling. The dose-response relationship above 10 mg is less linear, and pushing higher without CGM and metabolic panel confirmation of ongoing benefit is not advisable.

Injection Technique and Reconstitution

MOTS-c arrives as a lyophilised powder (typically in 5 mg or 10 mg vials). Reconstitute with bacteriostatic water — not sterile water, as bacteriostatic water allows multi-dose use over 28 days. Add the water slowly by injecting it down the side of the vial to avoid disturbing the lyophilised cake; never shake — swirl gently until the peptide dissolves.

Injection sites: Subcutaneous injection into the abdomen (lateral to the umbilicus), outer thigh, or lateral upper arm. Rotate sites with each injection to prevent localised lipoatrophy.

Storage: Lyophilised vials at room temperature or refrigerated. Reconstituted solution must be stored at 2–8 °C and used within 28 days. Do not freeze reconstituted peptide.

Needle gauge: 29–31 G, 8–13 mm insulin needle. Draw up with an 18 G needle to speed preparation, then swap to the injection needle.

Cycling Strategy

Like most peptides operating through receptor-mediated or pathway-mediated mechanisms, MOTS-c is usually cycled to maintain sensitivity and avoid tachyphylaxis of AMPK signalling pathways.

Standard cycle: 4–6 weeks on, 2–4 weeks off for most people.

Extended cycle (longevity protocols): Some integrative longevity practitioners use an 8-week on / 4-week off cycle, particularly when MOTS-c is combined with NAD+ precursors and other mitochondrial support. No tolerance issues have been described at this duration, but systematic data are absent.

Seasonal approach: Given MOTS-c’s parallels with exercise adaptation signals, practitioners often time cycles to high-volume training blocks (endurance athletes in base-building phase, for example), with off-cycles during de-load or travel periods.

During off-cycles, maintaining AMPK pathway activity through consistent aerobic exercise, time-restricted eating, and berberine or metformin (where indicated) preserves the baseline improvements achieved.

Who Benefits Most: Patient Selection

Strongest candidates:

• Metabolic syndrome with fasting insulin > 15 μIU/mL or HOMA-IR > 2.5
• Pre-diabetes (HbA1c 5.7–6.4%) with impaired glucose response on CGM
• Healthy-aging adults with age-related physical decline (VO2max decline, grip strength reduction)
• Non-tested recreational athletes seeking improved metabolic efficiency (MOTS-c falls under WADA S0, so it is prohibited at all times for athletes subject to anti-doping testing)
• Post-COVID patients with documented mitochondrial dysfunction (elevated lactate, low exercise tolerance out of proportion to cardiac/pulmonary findings)

Moderate candidates:

• People with elevated inflammatory biomarkers (CRP, IL-6) and metabolic inflexibility
• Women with PCOS and insulin resistance as the primary driver
• People on GLP-1 agonists who want to preserve or build muscle mass alongside fat loss (the interaction has never been studied)

Poor candidates / caution required:

• Active or recently treated malignancy (theoretical AMPK activation concerns; MOTS-c’s direct proliferative effect in cancer cells is not established, but precautionary logic applies)
• Pregnancy and breastfeeding (no safety data)
• Severe hepatic or renal impairment (human clearance of MOTS-c has not been characterised; no clinical guidance exists)

Stacking MOTS-c with Other Therapies

MOTS-c is frequently used within a broader mitochondrial support protocol. The combinations most commonly discussed:

MOTS-c + NAD+ IV: Rationale at the mitochondrial level: NAD+ replenishment supports the electron transport chain efficiency that MOTS-c’s AMPK activation depends upon. NAD+ IV infusions are typically scheduled on MOTS-c injection days during induction.

MOTS-c + Epithalon: For purely longevity-focused goals, this pairing addresses both mitochondrial metabolic function (MOTS-c) and telomere maintenance / pineal peptide axis (Epithalon). Epithalon is dosed separately on non-MOTS-c days to simplify the injection schedule.

MOTS-c + BPC-157: Relevant for musculoskeletal pathology alongside metabolic goals. BPC-157’s angiogenic and tissue-repair mechanisms are complementary rather than overlapping with MOTS-c’s metabolic-axis actions.

MOTS-c + Berberine or Metformin: AMPK-pathway stacking. Where cost or access limits peptide use, berberine (500 mg TID) maintains AMPK tone during off-cycles. In people already on metformin, MOTS-c does not appear to cause problematic redundancy — the mechanisms partially overlap but the magnitude of benefit appears additive in clinical observation.

None of these combinations has been tested in a human study; each adds its own unknowns.

Monitoring and Endpoints

Markers commonly tracked before starting MOTS-c and at the end of each cycle:

• Fasting glucose, insulin, HOMA-IR — primary metabolic endpoints
• HbA1c (if relevant to indication)
• Fasting lipids — MOTS-c tends to reduce triglycerides in metabolically dysregulated patients
• CGM trace (2-week wear) — captures post-prandial variability that fasting labs miss
• VO2max or 6-minute walk test — for physical-decline indication
• DEXA or BIA — lean mass and fat mass if body composition is a goal

Patient-reported outcomes that signal positive response include improved exercise session quality, reduced post-meal energy crash, better sleep quality (likely secondary to improved metabolic stability), and a subjective sense of physical resilience.

Known and theoretical risks

• Unknown human safety. No published human dosing data means unknown short- and long-term effects on glucose, hormones, the immune system and organs.
• Immunogenicity and impurities. The FDA states compounded drugs containing MOTS-c may pose a significant risk of immune reactions and have complexities with peptide-related impurities and characterisation [4].
• Metabolic effects in the wrong setting. A peptide that shifts glucose metabolism could interact with diabetes medicines, including insulin, metformin or GLP-1 drugs. That interaction has never been studied.
• Research-grade product quality. Peptides sold “for research use only” are not manufactured or tested to pharmaceutical standards. In test purchases of semaglutide from illegal online sellers, purity was 7.7 to 14.4 percent against a 99 percent label claim, and endotoxin was found in every sample [5].
• Injection-related harm. Self-injecting non-sterile material can cause abscesses, skin infections and, rarely, bloodstream infection.

Regulatory status

• United States (FDA). MOTS-c is not an approved drug. On the FDA page “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current as of 22 April 2026), MOTS-c is listed among substances previously in category 2 whose nominations were withdrawn. It is not on the 503A bulks list and not in category 1 (“under evaluation”) on the FDA list updated 14 May 2026 [4].
• EU and Germany. Not authorised as a medicinal product by the EMA or the BfArM. “Research use only” is a disclaimer, not a quality standard: such products are neither approved nor tested for human use.
• Sport (WADA 2026). Not named on the Prohibited List, but any pharmacological substance without current approval for human therapeutic use falls under S0 and is prohibited at all times [6].

When to talk to a physician

If you are interested in MOTS-c because of insulin resistance, prediabetes, fatigue, declining fitness or weight gain, start with a physician visit and basic labs: fasting glucose and insulin, HbA1c, lipids, thyroid and a review of medications. Those problems have treatments with strong evidence, including structured exercise, nutrition changes and, where indicated, approved medicines.

Exercise is the best-documented way to raise your own MOTS-c [2]. If you want to contribute to research, look for registered trials on clinicaltrials.gov or the EU Clinical Trials Register.

The Bottom Line

MOTS-c is a promising piece of mitochondrial biology with strong mouse data and an intriguing link to exercise in humans. The most common community pattern is 5–10 mg a week split into two or three injections; per-injection patterns of 5 mg three times weekly before training, and reference-site protocols of 5–10 mg three to five times weekly, run higher. All are extrapolated from that animal work and from practice; it has never been tested in a human treatment trial, and the FDA found no human exposure data. Get the metabolic basics measured first, keep exercising, and make any decision about MOTS-c with a physician who monitors glucose and insulin.

Related Articles

• MOTS-c: Mitochondrial Peptide Overview — What MOTS-c is, how it was discovered, and its biological significance
• Humanin Peptide Dosage Protocol — the sibling mitochondria-derived peptide
• Mitochondria and Longevity: Why Mitochondrial Health Is the Engine of Aging — The foundational science behind why mitochondrial peptides matter
• Epithalon Dosage Guide — Protocol comparison for another leading longevity peptide
• NAD+ IV Therapy: What to Expect — How NAD+ infusions complement MOTS-c’s mitochondrial effects
• Peptide Stacking Guide — How to combine multiple peptides